Login to Your Account

Endotis Pharma Obtains R&D of €4.5M from Public Sources

By James Etheridge

Wednesday, October 15, 2008

No Abstract


BioWorld International Correspondent

PARIS - Endotis Pharma, which is developing small-glyco drugs for applications in thrombosis and oncology, has obtained public funding of €4.5 million (US6.1 million) from three sources to finance ongoing research programs.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription